Monday, March 20, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

CIDR-GSK Partnership Spotlights Antifolates for TB Drug Discovery

by Global Biodefense Staff
October 15, 2015
Seattle BioMed Rebrands as Center for Infectious Disease Research

Scientists at the Center for Infectious Disease Research (CIDR), partnered with the Tres Cantos Open Lab Foundation at global pharmaceutical company GlaxoSmithKline to advance critically-needed treatments for Mycobacterium tuberculosis (Mtb).

The research conducted through the partnership indicates that antifolates may be a candidate for continued tuberculosis drug discovery.

“We thought we could identify antifolates with strong activity on Mtb, but we needed to collaborate with a leading edge pharmaceutical company to actually find them.”

“With tuberculosis killing 1.5 million people every year and current drugs diminishing in their effectiveness, this antifolate research is critical for finding new ways to treat TB,” said David Sherman, Ph.D., a professor at the Center for Infectious Disease Research.

Dr. Sherman and fellow CIDR researcher Anuradha Kumar, Ph.D., collaborated with GSK to curate a focused library of 2,508 potential antifolates, compounds that block production of folic acid and kill cells. The antifolates were then tested for activity against live Mtb and 17 active compounds were identified. The research revealed one antifolate is especially potent against Mtb, with numerous drug-like properties.

”The partnership with GSK was critical to the success of this project,” said Dr. Sherman. “We thought we could identify antifolates with strong activity on Mtb, but we needed to collaborate with a leading edge pharmaceutical company to actually find them.”

Currently, antifolates are typically used in cancer chemotherapies and to treat bacterial, fungal, and parasitic infections. There is also an approved antifolate used to treat the mycobacterial infection causing leprosy. However, work from the Sherman Lab and the Center for Infectious Disease Research demonstrated that analogues of the antifolate cancer chemotherapeutic methotrexate dramatically improved activity against TB in culture.

“Our next steps are to expand the chemistry around these molecules to identify compounds that could ultimately be administered effectively in humans,” said Dr. Sherman. “These compounds could literally be lifesavers for millions of people.”

CIDR is based in Seattle and is the largest independent, nonprofit organization in the U.S. focused solely on infectious disease research.

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC